BR112012013915A8 - anticorpos anti-c4. 4a e usos dos mesmos - Google Patents

anticorpos anti-c4. 4a e usos dos mesmos

Info

Publication number
BR112012013915A8
BR112012013915A8 BR112012013915A BR112012013915A BR112012013915A8 BR 112012013915 A8 BR112012013915 A8 BR 112012013915A8 BR 112012013915 A BR112012013915 A BR 112012013915A BR 112012013915 A BR112012013915 A BR 112012013915A BR 112012013915 A8 BR112012013915 A8 BR 112012013915A8
Authority
BR
Brazil
Prior art keywords
antibodies
antigen binding
binding regions
disorders
cancer
Prior art date
Application number
BR112012013915A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112012013915A2 (pt
Inventor
Mayer-Bartschmid Anke
Harrenga Axel
Stelte-Ludwig Beatrix
Dittmer Frank
Leder Gabriele
Tebbe Jan
Franz Juergen
Willuda Jörg
Linden Lars
Finnern Ricarda
Greven Simone
Cao Yong-Jiang
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of BR112012013915A2 publication Critical patent/BR112012013915A2/pt
Publication of BR112012013915A8 publication Critical patent/BR112012013915A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112012013915A 2009-12-09 2010-12-08 anticorpos anti-c4. 4a e usos dos mesmos BR112012013915A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09178474 2009-12-09
EP10170797 2010-07-26
PCT/EP2010/069216 WO2011070088A1 (en) 2009-12-09 2010-12-08 Anti-c4.4a antibodies and uses thereof

Publications (2)

Publication Number Publication Date
BR112012013915A2 BR112012013915A2 (pt) 2017-01-10
BR112012013915A8 true BR112012013915A8 (pt) 2017-12-26

Family

ID=43629588

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012013915A BR112012013915A8 (pt) 2009-12-09 2010-12-08 anticorpos anti-c4. 4a e usos dos mesmos

Country Status (27)

Country Link
US (2) US20120321619A1 (https=)
EP (2) EP2510012B1 (https=)
JP (3) JP5989544B2 (https=)
KR (1) KR101931820B1 (https=)
CN (1) CN102812047B (https=)
AR (1) AR079340A1 (https=)
AU (1) AU2010329904B2 (https=)
BR (1) BR112012013915A8 (https=)
CA (1) CA2783338A1 (https=)
CY (1) CY1119051T1 (https=)
DK (1) DK2510012T3 (https=)
ES (1) ES2632748T3 (https=)
HR (1) HRP20170973T1 (https=)
HU (1) HUE034847T2 (https=)
IL (1) IL219801A (https=)
IN (1) IN2012DN05175A (https=)
LT (1) LT2510012T (https=)
MX (1) MX2012006593A (https=)
NZ (1) NZ600470A (https=)
PL (1) PL2510012T3 (https=)
PT (1) PT2510012T (https=)
RS (1) RS56161B1 (https=)
RU (1) RU2577977C2 (https=)
SI (1) SI2510012T1 (https=)
TW (1) TWI488642B (https=)
WO (1) WO2011070088A1 (https=)
ZA (1) ZA201203498B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011158883A1 (ja) * 2010-06-15 2011-12-22 国立大学法人大阪大学 癌予後判定可能な抗体、および癌予後判定方法
KR102023496B1 (ko) * 2011-04-21 2019-09-20 시애틀 지네틱스, 인크. 신규 결합제-약물 콘주게이트 (adc) 및 그의 용도
JP2014117191A (ja) * 2012-12-13 2014-06-30 Fisheries Research Agency リン酸化中性スフィンゴミエリナーゼ１、抗リン酸化中性スフィンゴミエリナーゼ１抗体、中性スフィンゴミエリナーゼ１変異体、及びそれらの用途
US10428159B2 (en) 2014-09-09 2019-10-01 Board Of Regents, The University Of Texas System Blocking monoclonal antibodies to AGR2 and its receptor C4.4A
WO2016166169A1 (en) 2015-04-17 2016-10-20 Spring Bioscience Corporation Antibodies, compositions, and immunohistochemistry methods for detecting c4.4a
AU2016365423A1 (en) * 2015-12-04 2018-07-12 The Regents Of The University Of California Novel antibodies for the treatment of cancers
WO2017156280A1 (en) * 2016-03-09 2017-09-14 Viba Therapeutics, Inc. Methods of treating cancer using monoclonal antibodies to agr2 and c4.4a
JP7617603B2 (ja) 2017-01-11 2025-01-20 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ｒ－スポンジン（ｒｓｐｏ）サロゲート分子
JP7305543B2 (ja) 2017-01-26 2023-07-10 スロゼン オペレーティング， インコーポレイテッド 組織特異的Ｗｎｔシグナル増強分子およびその使用
JP7052389B2 (ja) * 2018-02-07 2022-04-12 株式会社三洋物産 遊技機
JP2021530223A (ja) 2018-07-09 2021-11-11 スロゼン， インコーポレイテッド 組織特異性Ｗｎｔシグナル増強分子及びその使用
JP2021530238A (ja) * 2018-07-20 2021-11-11 デューク ユニバーシティ がんの処置のための抗ｌｙｐｄ３ ｃａｒ ｔ細胞療法
KR102887141B1 (ko) * 2018-11-08 2025-11-17 고쿠리츠다이가쿠호우징 카가와다이가쿠 희소당 함유 조성물의 제조 방법 및 희소당 함유 조성물
CN111349164B (zh) * 2018-12-21 2023-05-26 艾比玛特医药科技（上海）有限公司 糖基磷脂酰肌醇锚定糖蛋白（c4.4a）的单克隆抗体及其应用
EP3986461A4 (en) 2019-06-21 2023-07-05 Children's National Medical Center METHODS AND COMPOSITION FOR A BINDING MOLECULE TARGETING CANCER CELLS EXPRESSING SSX2 PEPTIDE 41-49 IN THE HLA-A*0201 CONTEXT
TW202134278A (zh) 2019-11-08 2021-09-16 美商胡曼尼根公司 用於治療腫瘤之ｅｐｈａ３導向ｃａｒ－ｔ細胞
TW202233656A (zh) 2020-11-16 2022-09-01 美商蘇羅森營運公司 肝特異性wnt訊號增強分子及其用途
IL315431A (en) 2022-03-16 2024-11-01 Pentixapharm Ag Antibodies against lypd3
EP4536278A2 (en) 2022-06-07 2025-04-16 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
ES2169864T3 (es) * 1996-05-31 2002-07-16 Health Research Inc Anticuerpos monoclonales anti-endoglina y su uso en terapia anti-angiogenesis.
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1220919A2 (en) * 1999-09-29 2002-07-10 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Metastasis-associated antigen c4.4a
AU2002329540A1 (en) * 2001-06-20 2003-01-02 Morphosys Ag Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
KR20120064120A (ko) * 2004-06-01 2012-06-18 제넨테크, 인크. 항체 약물 접합체 및 방법
DK2117571T3 (en) * 2006-12-08 2017-05-08 Monopar Therapeutics Inc Urokinase-type plasminogen activator receptor epitope
KR102023496B1 (ko) * 2011-04-21 2019-09-20 시애틀 지네틱스, 인크. 신규 결합제-약물 콘주게이트 (adc) 및 그의 용도

Also Published As

Publication number Publication date
TWI488642B (zh) 2015-06-21
AU2010329904B2 (en) 2015-07-09
SI2510012T1 (sl) 2017-08-31
HRP20170973T1 (hr) 2017-09-22
EP3144323A3 (en) 2017-05-31
BR112012013915A2 (pt) 2017-01-10
MX2012006593A (es) 2012-06-28
EP2510012B1 (en) 2017-04-19
KR101931820B1 (ko) 2018-12-21
US20120321619A1 (en) 2012-12-20
CA2783338A1 (en) 2011-06-16
DK2510012T3 (en) 2017-07-31
CY1119051T1 (el) 2018-01-10
JP2016104820A (ja) 2016-06-09
CN102812047A (zh) 2012-12-05
WO2011070088A1 (en) 2011-06-16
NZ600470A (en) 2015-02-27
KR20120116958A (ko) 2012-10-23
RU2577977C2 (ru) 2016-03-20
CN102812047B (zh) 2015-08-26
RU2012128343A (ru) 2014-01-20
HK1178920A1 (en) 2013-09-19
IN2012DN05175A (https=) 2015-10-23
EP3144323A2 (en) 2017-03-22
PT2510012T (pt) 2017-07-13
AU2010329904A1 (en) 2012-06-14
EP2510012A1 (en) 2012-10-17
AR079340A1 (es) 2012-01-18
HUE034847T2 (en) 2018-03-28
LT2510012T (lt) 2017-07-25
JP2018019721A (ja) 2018-02-08
PL2510012T3 (pl) 2017-09-29
US20170158775A1 (en) 2017-06-08
IL219801A (en) 2016-08-31
ZA201203498B (en) 2015-10-28
TW201134485A (en) 2011-10-16
RS56161B1 (sr) 2017-11-30
IL219801A0 (en) 2012-07-31
JP5989544B2 (ja) 2016-09-07
JP2013513369A (ja) 2013-04-22
ES2632748T3 (es) 2017-09-15
JP6240696B2 (ja) 2017-11-29

Similar Documents

Publication Publication Date Title
BR112012013915A8 (pt) anticorpos anti-c4. 4a e usos dos mesmos
BRPI0819909B8 (pt) anticorpo sintético humano ou humanizado isolado ou um fragmento funcional do mesmo, fragmento funcional e composição farmacêutica
BR112022014667A2 (pt) Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos
BRPI0808940A8 (pt) anticorpo humano ou fragmento de ligação do mesmo, antígeno, polinucleotídeo, vetor, célula hospedeira, método para preparar um anticorpo ou um fragmento de ligação ou cadeia(s) de imunoglobulina do mesmo, anticorpo, cadeia de imunoglobulina ou um fragmento de ligação do mesmo, composição, usos do anticorpo ou fragmento de ligação, de um antígeno, de um polinucleotídeo, de um vetor, ou de uma célula, e de uma molécula de ligação a antígeno tumoral, método para clonagem molecular de um anticorpo, e, kit para o diagnóstico de um tumor
BR112019001922A2 (pt) receptores de célula t e imunoterapia usando os mesmos
BR112017010110A2 (pt) anticorpos contra cd73 e usos do mesmo
BR112022004047A2 (pt) Proteínas de ligação multiespecíficas para o tratamento de câncer
CL2013002203A1 (es) Molecula de union a antigeno (abm) que se une al antigeno carcinoembrionario humano (cea) unido a membrana; anticuerpo que se une a cea unido a membrana; polinucleotido que los codifica; vector; celula huesped; composicion que comprende al abm o al anticuerpo; y su uso para tratar un cancer que expresa niveles anormales de cea.
BR112016000889A2 (pt) composição e vacina para tratamento de câncer de próstata
BR122020002402B8 (pt) Proteína de ligação de antígeno isolada recombinante que liga il-23, composição farmacêutica, molécula de ácido nucleico isolada recombinante, vetor recombinante, célula hospedeira recombinante, métodos de confecção da referida proteína de ligação e uso da mesma
BR112018005573A2 (pt) ?polipeptídeos de ligação a cd3?
BR112014026531A2 (pt) proteínas de ligação de antígeno ligando cd30 humano
MX2009013765A (es) Polipeptidos y polinucleotidos para artemina y ligandos relacionados, y metodos de uso de los mismos.
BR112015017800A2 (pt) moléculas de ligação ao antígeno biespecífica ativadora de célula t, polinucleotídeo, polipeptídeo, vetor, célula hospedeira, método de produção da molécula de ligação ao antígeno biespecífica ativadora de célula t, composição farmacêutica e uso da molécula de ligação ao antígeno biespecífica ativadora de célula t
EA201590986A1 (ru) Антитела к ceacam5 и их применения
CL2007003649A1 (es) Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70.
MX390894B (es) Polipéptido de fusión anti-cáncer.
BR112021009275A2 (pt) Anticorpo humanizado anti-sirp alfa ou um fragmento de ligação a antígeno do mesmo, composição farmacêutica, molécula de ácido nucleico, e, célula hospedeira.
BR112014024282A2 (pt) anticorpos ligantes ao receptor b1 da bradicinina
CL2009000862A1 (es) Anticuerpo aislado, derivados o fragmentos aislados del mismo capaz de unirse a la proteina cd151, composición que lo comprende; ácido nucleico que lo codifica, vector y célula huesped que lo comprenden; procedimiento para preparar dicho anticuerpo; util como medicamento para prevenir o tratar el cáncer.
BR112014029089A2 (pt) anticorpo ou um fragmento de ligação de antígeno do mesmo; polinucleótido codificador; composto; composição/formulação farmacêutica; kit; uso; método in vitro para reduzir ou inibir a atividade da enzima tg2
BR112022012327A2 (pt) Anticorpos ou fragmentos dos mesmos, ácido nucleico, vetor e célula hospedeira
BR112013021056A2 (pt) anticorpo monoclonal, linhagem de células de hibridoma, kit para diagnóstico, métodos para a produção de um anticorpo monoclonal e de um agente de ligação, agente de ligação sequência de aminoácidos purificada, método para a obtenção de uma sequência do ácido nucleico codificante, molécula do ácido nucleico isolado codificante, vetor, célula hospedeira isolada, proteína de fusão, método de triagem para a presença de uma doença, de uma condição, métodos de diagnóstico de um indivíduo, de prognóstico para um indivíduo, e de monitoramento de um indivúdo, e, método para detecção da presença ou ausência de um câncer cervical
Kanda et al. Fascin regulates chronic inflammation‐related human colon carcinogenesis by inhibiting cell anoikis
BR112017027702A2 (pt) anticorpos antirreceptor do fator de crescimento endotelial vascular 2 (vegfr2)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]